アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine 150 mg - ranitidine tablets, usp is indicated in: 1. short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). 4. short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

carilion materials management - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine 15 mg in 1 ml - ranitidine oral solution is indicated in: - short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. - the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). - short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. - maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried out

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

unit dose services - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine 15 mg in 1 ml - ranitidine oral solution usp is indicated in: - short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. - the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). - short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. - maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried

マルタ - 英語 - Medicines Authority

syri pharma limited floor 0 1 wml, 1 windmill lane dublin 2, d02 f206, ireland - ranitidine hydrochloride - oral solution - ranitidine hydrochloride 15 mg/ml - drugs for acid related disorders

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - ranitidine hydrochloride -

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - ranitidine hydrochloride -

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - ranitidine hydrochloride - oral tablet - 75mg

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

viatris limited - ranitidine hydrochloride 167.5mg equivalent to ranitidine 150 mg - film coated tablet - 150 mg - active: ranitidine hydrochloride 167.5mg equivalent to ranitidine 150 mg excipient: castor oil colloidal silicon dioxide croscarmellose sodium hypromellose e-15 iron oxide yellow isopropyl alcohol magnesium stearate microcrystalline cellulose purified talc   purified water titanium dioxide - long lasting relief from acid indigestion, heartburn and symptoms resulting from excess stomach acid.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

viatris limited - ranitidine hydrochloride 167.5mg equivalent to ranitidine 150 mg - film coated tablet - 150 mg - active: ranitidine hydrochloride 167.5mg equivalent to ranitidine 150 mg excipient: castor oil colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide yellow isopropyl alcohol magnesium stearate microcrystalline cellulose purified talc   purified water titanium dioxide - is indicated for the treatment of duodenal ulcer, and benign gastric ulcer, including that associated with non-steroidal anti- inflammatory agents.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

viatris limited - ranitidine hydrochloride 335 equivalent to ranitidine 300 mg - film coated tablet - 300 mg - active: ranitidine hydrochloride 335 equivalent to ranitidine 300 mg excipient: castor oil colloidal silicon dioxide croscarmellose sodium hypromellose e-15 iron oxide yellow isopropyl alcohol magnesium stearate microcrystalline cellulose purified talc   purified water titanium dioxide - long lasting relief from acid indigestion, heartburn and symptoms resulting from excess stomach acid.